Skip to main content
Vistin Pharma logo

Vistin Pharma — Investor Relations & Filings

Ticker · VISTN ISIN · NO0010734122 LEI · 5967007LIEEXZXFQY092 OL Manufacturing
Open in API
Filings indexed 519 across all filing types
Latest filing 2021-04-23 Annual Report
Country NO Norway
Listing OL VISTN

About Vistin Pharma

https://www.vistin.com/

Vistin Pharma is a pharmaceutical company specializing in the production of Metformin Hydrochloride, an Active Pharmaceutical Ingredient (API). The company operates as a pure-play, global supplier, providing high-quality Metformin to pharmaceutical companies worldwide. In addition to the standard API, Vistin Pharma offers specialized grades such as Direct Compressible (DC) Metformin. With over 50 years of experience, the company emphasizes sustainable manufacturing from its dedicated European production facility.

Recent filings

Filing Released Lang Actions
Vistin Pharma ASA: Annual Report for 2020
Annual Report Classification · 100% confidence The document is titled 'ANNUAL REPORT 2020' and contains comprehensive sections including the Directors' Report, financial results, liquidity and financial position, events after the balance sheet date, organizational matters, and corporate social responsibility. It provides detailed financial data and management analysis for the full fiscal year 2020, fitting the definition of an Annual Report (10-K). FY 2020
2021-04-23 Norwegian
Vistin Pharma ASA: Annual Report for 2020
Report Publication Announcement Classification · 98% confidence The document text is very short (593 characters) and explicitly states: 'Please find attached the Annual Report for 2020 for Vistin Pharma ASA.' It also mentions where the report will be made available online. This structure—a brief announcement stating that a full report is attached or published—fits the definition of a Report Publication Announcement (RPA) rather than the Annual Report (10-K) itself, adhering to the 'MENU VS MEAL' rule. The title mentions 'Annual Report for 2020', but the content is an announcement of that report.
2021-04-23 English
Vistin Pharma ASA: First quarter 2021 financial results
Investor Presentation Classification · 95% confidence The document is a detailed presentation titled 'Vistin Pharma – First quarter 2021 results'. It contains comprehensive financial data, including consolidated income statements, balance sheets, operational reviews, and outlooks for the first quarter of 2021. It is clearly an investor-facing presentation detailing quarterly performance, which fits the definition of an Investor Presentation (IP) as it focuses on financials, strategy, and market position, while also serving as an Interim/Quarterly Report (IR) due to the inclusion of substantive financial statements. Given the format (slides, agenda, highlights), it is best classified as an Investor Presentation. Q1 2021
2021-04-23 Norwegian
Vistin Pharma ASA: First quarter 2021 financial results
Interim / Quarterly Report Classification · 100% confidence The document is a comprehensive financial report for Vistin Pharma ASA for the first quarter of 2021. It includes detailed financial statements (P&L, balance sheet, cash flow), management commentary on operational status, market outlook, and risk factors. It is not an announcement of a report, but the report itself, containing substantive financial data and analysis for an interim period. Q1 2021
2021-04-23 Norwegian
Vistin Pharma ASA: First quarter 2021 financial results
Earnings Release Classification · 98% confidence The document is titled "Vistin Pharma ASA: First quarter 2021 financial results" and provides key financial highlights (revenue, EBITDA, net profit, cash position) for Q1 2021. It explicitly mentions that the conference call will be held today and concludes with the statement: "Please find the Q1 report and presentation enclosed." This structure—providing key results and announcing an accompanying call/report—is characteristic of an Earnings Release (ER). Although it mentions the Q1 report is enclosed, the primary function of this short text is the initial announcement of the period's results, making ER the most appropriate classification over RPA, as it contains substantive financial figures, not just a notice of publication. Q1 2021
2021-04-23 English
Vistin Pharma ASA: Invitation to Q1 2021 conference call
Call Transcript Classification · 98% confidence The document is an invitation for a conference call regarding the release of the first quarter 2021 results. It explicitly mentions hosting a 'conference call for all shareholders and interested parties' followed by a 'Q&A session' and provides dial-in details and a webcast link. This content perfectly matches the definition of a Call Transcript (CT) event, as it is the announcement/invitation for the call where the transcript would originate. However, since the document is an *invitation* to the call, and not the transcript itself, it is more accurately classified as an announcement related to an earnings event. Given the options, the content is directly related to the earnings release event (ER) or the call itself (CT). Since it specifically details the conference call logistics, 'Call Transcript' (CT) is the most precise fit for the event being announced, even though this specific text is the invitation. If the text were the actual transcript, CT would be certain. As it is the invitation to the earnings call, it is closely related to the ER, but the focus is the call mechanics. Given the strong focus on the call details (dial-in, Q&A), CT is chosen over ER (which is usually just the highlights).
2021-04-16 English

Browse filings by year

12 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.